Article
Enhertu's groundbreaking HER2-low breast cancer nod could come this year as AZ, Daiichi seek ambitious approval
Rating:
0.0
Views:
62
Likes:
1
Library:
1
After winning a standing ovation at the recent American Society of Clinical Oncology meeting, Enhertu's HER2-low breast cancer data are now getting the VIP treatment at the FDA. | After winning a standing ovation at the recent ASCO event, Enhertu's HER2-low breast cancer data are now getting the VIP treatment at the FDA. And AstraZeneca and Daiichi Sankyo are targeting an ambitiously broad patient population.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value